Incidental Detection of Pleomorphic Sarcoma on 68Ga-PSMA PET/CT in a Patient With Prostate Cancer
Related Experiment Video
Updated: Jan 20, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
Boon Mathew1, Archi Agrawal1, Nilendu C Purandare1
1From the Departments of Nuclear Medicine and Molecular Imaging.
Abstract:
Ga prostate-specific membrane antigen (PSMA) PET/CT is used in the staging, evaluation of biochemical recurrence, and response assessment of patients with prostate cancer. In addition to the PSMA-expressing prostate cancer cells, Ga-PSMA binds to the neovasculaature of various other solid tumors and benign lesions. We report a case of a 72-year-old man with recently diagnosed adenocarcinoma of prostate, incidentally found to have pleomorphic sarcoma on the staging Ga-PSMA PET/CT.
More Related Videos
10:28Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
08:03Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells
Published on: October 20, 2015
Related Concept Videos
05:19A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
10:28Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
02:39An In Vivo PET Imaging Technique to Detect Tumors in a Murine Model Using Radiolabeled Antibodies
08:03Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells
10:02Whole-body PET/MRI of Pediatric Patients: The Details That Matter
TSPO-PET/CT Imaging to Detect Infarct Formation in a Mouse Model of Ischemic Stroke